Innovex's 20% Q2 EBITDA Margin Passes the Smell Test-But the $95 Million Bet Comes First

Q2 results were strong, but TCO is the stock's next real test

Innovex's second quarter was hard to argue with: Q2 revenue of $245 million, adjusted EBITDA of $48 million, and a 20% adjusted EBITDA margin. That is a credible operating scorecard and a sign that execution is holding up.

The more important decision, though, is the TCO acquisition. Innovex closed the deal on July 1, 2026, in a $95 million cash-and-stock deal. The company's cash position and lack of bank debt suggest this is not the kind of purchase that should stress the balance sheet. TCO is projected to add $70 million of 2025 revenue, $17.6 million of 2025 adjusted EBITDA, and a 25% adjusted EBITDA margin. If integration stays clean, that can support gradual compounding rather than dramatic storytelling.

So the core question is straightforward: should Innovex be valued as a steady operator, or is the market starting to price a more acquisitive growth story?

The quarter looked operationally solid, not just cosmetically strong

A good quarter can look convincing in a spreadsheet. The better check is whether revenue is growing, cash is collecting, and customers are still awarding business. By those measures, Innovex's latest quarter held up well.

Revenue growth and cash conversion were both healthy

Innovex said revenue was up 2% quarter-over-quarter and up 9% year-over-year. That matters because margin pressure can be managed, but sustained revenue growth usually reflects real customer demand.

The cash profile also looked healthy. Innovex reported net income of $25 million, net cash provided by operating activities of $37 million, and free cash flow of $30 million. It ended the quarter with $222 million of cash and cash equivalents and no bank debt. That combination makes it harder to argue that the quarter was being propped up by financial engineering.

Customer wins and product trials point to real demand

Management said it completed the first successful XPak trial with a major independent oil company in Asia. A trial is not full-scale revenue, but it is still a useful early sign that customers see value in the technology.

The award window is a stronger signal. Innovex was awarded an additional $20 million subsea tension riser package for an operator in Malaysia, with follow-on wellhead awards anticipated. That suggests demand is holding, not fading.

The merged Dril-Quip and Innovex platform is also starting to show up in practice. The company highlighted the first installation of the ArgoLATCH Subsea Release Plug in a deepwater exploration well in Brazil and said its Canadian wellhead team completed its first surface wellhead delivery to Mexico during the quarter. That fits the merger rationale that innovative product integration ensures seamless transitions from one well phase to the next.

Watch three things from here: - whether revenue growth persists beyond one quarter - whether the Malaysia award leads to the expected follow-on wellhead awards - whether operating cash flow stays strong enough to support integration without balance-sheet strain

TCO is the real catalyst, and timing matters

With a close expected in early Q3 already in view, the practical question for investors is simple: get involved before the market fully capitalizes the acquisition, or wait and risk paying up for a story that is already clearer.

The economics look manageable on paper

This is not a balance-sheet-stretching transformation. Innovex is buying TCO for $95 million, and the basic math is sensible. TCO is projected to bring $70 million of 2025 revenue and $17.6 million of 2025 adjusted EBITDA at a 5.4x 2025 adjusted EBITDA price. Management also says the deal is accretive to EPS and should leave the company with a $111 million adjusted net cash position after closing.

That matters because the base business already looks stable. Innovex just reported $48 million of adjusted EBITDA, $30 million of free cash flow, and $222 million of cash and cash equivalents with no bank debt. In plain terms, this looks like a strong operator buying a smaller profitable asset, not a fragile company reaching for growth.

The bull case and the main risk

The bull case is straightforward. TCO strengthens Innovex in Norway and the UAE and adds technologies such as completion barrier plugs and annulus pressure relief systems. That is the sort of fit that can improve customer coverage and support follow-on wins without turning the business into a debt-fueled story.

The main risk is capital allocation drift. Today the deal is small and disciplined. The concern is that management begins to rely too heavily on acquisitions instead of letting the core business and integration do the heavy lifting.

If the acquisition integrates cleanly and the base business keeps delivering steady operating performance, the valuation case can improve. If not, this could turn from a sensible bolt-on purchase into just another acquisition narrative.